French deeptech startup Cementic has secured $4.6 million in seed funding to advance its innovative dental biomaterials. The round was led by the private investment club Blast, founded by Anthony Bourbon, alongside contributions from numerous dental professionals. The capital will accelerate the development of a nanomaterial designed to improve the success rates of common dental procedures.
Cementic Enters a New Growth Phase
Founded in 2021 by Dr. Samir Raddi, Cementic focuses on creating advanced materials for dental care. The startup aims to transform its laboratory research into practical, patient-ready solutions with this latest funding. Early-stage investments from practicing dentists highlight the potential clinical impact of the technology.
Clinical Trials to Begin in France
Cementic plans to launch its first trials in France later this year across partner dental clinics. These trials will test the material in real-world conditions, directly on patients undergoing routine procedures. By collecting clinical data, the startup hopes to validate both the safety and effectiveness of its solution.
A Solution to Reduce Post-Treatment Infections
The company’s material is used as a dental filler at the end of root canal procedures, a treatment prone to post-operative complications. Dr. Raddi notes that despite being common, these procedures still carry a notable risk of failure and infection, sometimes requiring repeat interventions. Cementic’s solution is designed to minimize infections, inflammation, and the need for additional dental work.
Laboratory Results and Antibiotic Reduction
Initial lab tests indicate the material can eliminate 99.99% of bacteria that survive standard treatment, offering a significant improvement over current methods. This capability may reduce reliance on antibiotics, which are frequently prescribed to prevent post-treatment infections. By targeting bacterial persistence, Cementic seeks to enhance patient outcomes and streamline recovery.
Market Expansion Plans
Cementic’s research has spanned France, including Paris-Saclay, and the United States, particularly Silicon Valley, resulting in a technology protected by two patents. The startup anticipates launching in the U.S. market within six months, while European approval and commercialization could take 18 to 24 months. Long-term ambitions include adapting the technology for other medical applications, such as bone and ocular treatments.
Strategic Partnerships and Industry Support
The involvement of Blast and dental professionals will support critical clinical and industrial partnerships. These collaborations are essential for integrating the material into everyday dental practice. Cementic’s approach underscores the importance of combining scientific innovation with practical industry expertise to drive adoption.
With this $4.6 million seed round, Cementic positions itself at the forefront of dental biomaterials innovation. Its nanomaterial could significantly reduce post-treatment infections and improve patient outcomes. The startup now embarks on a pivotal phase, moving from laboratory success to real-world clinical validation and international market entry.